Company profile
Precision BioSciences, Inc.
NASDAQ: DTIL · Healthcare · Biotechnology
#484 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
46DFH 44DQ 55GM 34SS 51
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ Piotroski F, revenue growth (YoY)
Methodology →Revenue TTM
$45.1M
Rev growth YoY (TTM)
-11.9%
Net income (FY)
-$45.7M
Employees
67
as of 2026-08-18
Market cap
$102.9M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$34.3M$34.3M2025
Net income-$45.7M-$45.7M2025
Operating income-$52.1M-$52.1M2025
Total assets$154.4M$154.4M2025
Liabilities$62.2M$62.2M2025
Equity$92.2M$92.2M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License100%
By geography
Not disclosed.
The read
What is Precision BioSciences, Inc.’s revenue?
Precision BioSciences, Inc. booked $34.3M in FY2025 revenue, contracting 50% year over year — slower than 82% of Healthcare companies we track, at a -133.4% net margin.
Peers · Healthcare
Leef Brands Inc.57CSenseonics Holdings, Inc.57CX4 Pharmaceuticals, Inc.51DRapid Micro Biosystems, Inc.46DOrchestra BioMed Holdings, Inc.46DArcus Biosciences, Inc.47DNeighbors
Durham →Key facts
CEOMichael Amoroso
SectorHealthcare
IndustryBiotechnology
HeadquartersDurham, NC
ExchangeNASDAQ: DTIL
Employees67
IPO date2019-03-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.